Vitamin Shoppe, Inc (NYSE:VSI) Given “Sell” Rating at Goldman Sachs Group, Inc. (The)

Vitamin Shoppe, Inc (NYSE:VSI)‘s stock had its “sell” rating restated by analysts at Goldman Sachs Group, Inc. (The) in a research note issued to investors on Thursday. They currently have a $6.00 price target on the specialty retailer’s stock, down from their prior price target of $13.00. Goldman Sachs Group, Inc. (The)’s price objective suggests a potential downside of 3.23% from the stock’s current price.

Several other research firms also recently commented on VSI. Barclays PLC reaffirmed an “equal weight” rating and set a $13.00 price objective (down from $24.00) on shares of Vitamin Shoppe in a research note on Sunday, May 14th. BidaskClub downgraded Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. ValuEngine downgraded Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Gabelli downgraded Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Zacks Investment Research downgraded Vitamin Shoppe from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 13th. Two research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. The company currently has an average rating of “Hold” and an average target price of $15.71.

Shares of Vitamin Shoppe (NYSE VSI) opened at 6.20 on Thursday. Vitamin Shoppe has a 12-month low of $5.75 and a 12-month high of $28.56. The company’s 50-day moving average price is $10.47 and its 200 day moving average price is $15.91. The firm’s market capitalization is $144.03 million.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings data on Wednesday, August 9th. The specialty retailer reported $0.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.39 by $0.16. The company had revenue of $304.84 million for the quarter, compared to analysts’ expectations of $314.74 million. Vitamin Shoppe had a negative net margin of 11.98% and a positive return on equity of 8.33%. The firm’s revenue was down 8.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.55 earnings per share. On average, equities research analysts forecast that Vitamin Shoppe will post $0.98 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Vitamin Shoppe, Inc (NYSE:VSI) Given “Sell” Rating at Goldman Sachs Group, Inc. (The)” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/vitamin-shoppe-inc-nysevsi-given-sell-rating-at-goldman-sachs-group-inc-the.html.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Vitamin Shoppe by 14.8% in the first quarter. Vanguard Group Inc. now owns 2,186,549 shares of the specialty retailer’s stock worth $44,059,000 after buying an additional 282,598 shares during the period. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Vitamin Shoppe by 6.8% in the first quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,910,081 shares of the specialty retailer’s stock worth $38,488,000 after buying an additional 122,445 shares during the period. FMR LLC increased its position in shares of Vitamin Shoppe by 32.4% in the second quarter. FMR LLC now owns 1,254,690 shares of the specialty retailer’s stock worth $14,617,000 after buying an additional 307,050 shares during the period. Olstein Capital Management L.P. increased its position in shares of Vitamin Shoppe by 22.9% in the first quarter. Olstein Capital Management L.P. now owns 802,133 shares of the specialty retailer’s stock worth $16,163,000 after buying an additional 149,338 shares during the period. Finally, State Street Corp increased its position in shares of Vitamin Shoppe by 9.2% in the first quarter. State Street Corp now owns 721,483 shares of the specialty retailer’s stock worth $14,535,000 after buying an additional 60,575 shares during the period.

About Vitamin Shoppe

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply